Mr. Don Kennard joined Halozyme in 2004 with extensive senior management experience in the fields of regulatory affairs (RA), clinical programs, and quality assurance (QA). He has worked directly with the FDA, as well as regulatory authorities of various foreign ministries of health, to secure registration, authorize commercialization, and successfully implement quality programs, for a broad range and extensive number of product approvals across pharmaceuticals, biologics, medical devices and diagnostics. Prior to joining Halozyme, Mr. Kennard served as Vice President of Worldwide RA/QA at Quidel, Inc., a manufacturer of diagnostic products, where he led the RA/QA and clinical functions, while also establishing a Quality System CE marking program that enabled Quidel to expand and sustain sales in the European Union. From 1991 to 2001, he was Vice President of Research and Development, Regulatory Affairs, Clinical and Quality Assurance for Nobel Biocare, Inc. and Steri-Oss (acquired by Nobel Biocare). From 1981 to 1991, Mr. Kennard was Director of RA/QA at Allergan, Inc. for prescription and OTC ophthalmic and dermatological drugs, injectable drugs, biotechnology products and ophthalmic products. Prior to Allergan, he was Director of Quality Control at B. Braun. Mr. Kennard holds a B.S. in microbiology from the University of California, Long Beach.